KR102246699B1 - 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도 - Google Patents

암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도 Download PDF

Info

Publication number
KR102246699B1
KR102246699B1 KR1020187029952A KR20187029952A KR102246699B1 KR 102246699 B1 KR102246699 B1 KR 102246699B1 KR 1020187029952 A KR1020187029952 A KR 1020187029952A KR 20187029952 A KR20187029952 A KR 20187029952A KR 102246699 B1 KR102246699 B1 KR 102246699B1
Authority
KR
South Korea
Prior art keywords
cancer
nucleosome
tissue
transcription factor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187029952A
Other languages
English (en)
Korean (ko)
Other versions
KR20190013707A (ko
Inventor
제이콥 빈센트 미칼레프
조지 레이스-필류
Original Assignee
벨지언 볼리션 에스피알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55968658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102246699(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 벨지언 볼리션 에스피알엘 filed Critical 벨지언 볼리션 에스피알엘
Priority to KR1020217012412A priority Critical patent/KR102369544B1/ko
Publication of KR20190013707A publication Critical patent/KR20190013707A/ko
Application granted granted Critical
Publication of KR102246699B1 publication Critical patent/KR102246699B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57488—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187029952A 2016-03-22 2017-03-22 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도 Expired - Fee Related KR102246699B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217012412A KR102369544B1 (ko) 2016-03-22 2017-03-22 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1604806.8 2016-03-22
GBGB1604806.8A GB201604806D0 (en) 2016-03-22 2016-03-22 Method of identifying a cancer of unknown origin
PCT/EP2017/056851 WO2017162755A1 (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217012412A Division KR102369544B1 (ko) 2016-03-22 2017-03-22 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도

Publications (2)

Publication Number Publication Date
KR20190013707A KR20190013707A (ko) 2019-02-11
KR102246699B1 true KR102246699B1 (ko) 2021-05-04

Family

ID=55968658

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187029952A Expired - Fee Related KR102246699B1 (ko) 2016-03-22 2017-03-22 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도
KR1020217012412A Expired - Fee Related KR102369544B1 (ko) 2016-03-22 2017-03-22 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217012412A Expired - Fee Related KR102369544B1 (ko) 2016-03-22 2017-03-22 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도

Country Status (12)

Country Link
US (1) US20200363418A1 (https=)
EP (3) EP3433616B2 (https=)
JP (1) JP6777757B2 (https=)
KR (2) KR102246699B1 (https=)
CN (1) CN109313192B (https=)
AU (1) AU2017238442A1 (https=)
CA (1) CA3018428C (https=)
ES (2) ES2861440T5 (https=)
GB (1) GB201604806D0 (https=)
MY (1) MY187655A (https=)
SG (1) SG11201807991QA (https=)
WO (1) WO2017162755A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202242130A (zh) * 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
US20240318259A1 (en) * 2021-09-24 2024-09-26 Oncocross Co., Ltd. Method for determining primary tumor site
WO2025073909A1 (en) 2023-10-04 2025-04-10 Belgian Volition Srl Pcr method for detecting ctcf occupied cfdna fragments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160003848A1 (en) 2013-02-28 2016-01-07 Singapore Volition Pte Limited Method for predicting therapy efficacy using nucleosome structure biomarkers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249548A1 (en) * 2000-03-27 2001-10-08 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
ES2399110T3 (es) * 2001-09-14 2013-03-25 F. Hoffmann-La Roche Ag Diagnóstico diferencial de los trastornos del metabolismo del hierro por medio de cuatro parámetros independientes y recomendaciones para el tratamiento de estos trastornos del metabolismo del hierro
US7248921B2 (en) * 2003-06-02 2007-07-24 Cameron Health, Inc. Method and devices for performing cardiac waveform appraisal
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040236188A1 (en) * 2003-05-19 2004-11-25 Ge Medical Systems Information Method and apparatus for monitoring using a mathematical model
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
JP4873510B2 (ja) * 2008-07-01 2012-02-08 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤
MY148542A (en) * 2009-06-15 2013-04-30 Cancer Res Initiatives Foundation A method for the assessment of cancer in a biological sample obtained from a subject
EP2270510A1 (en) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
CN104067125B (zh) * 2011-12-07 2017-12-26 比利时意志有限责任公司 用于检测核小体加合物的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160003848A1 (en) 2013-02-28 2016-01-07 Singapore Volition Pte Limited Method for predicting therapy efficacy using nucleosome structure biomarkers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ballare Cecilia et al, Molecular Cell (2012.11.21.), vol 49, no 1, pp 67-79.
Paschalia Pantazi et al, Research and Reports in Biochemistry (2015.01.13.), 2015: 5, pp 11-30.

Also Published As

Publication number Publication date
ES2861440T3 (es) 2021-10-06
EP4270007A3 (en) 2023-12-20
KR102369544B1 (ko) 2022-03-03
WO2017162755A1 (en) 2017-09-28
EP3839513B1 (en) 2023-06-14
EP3433616B2 (en) 2024-07-24
EP3433616A1 (en) 2019-01-30
KR20190013707A (ko) 2019-02-11
KR20210049954A (ko) 2021-05-06
US20200363418A1 (en) 2020-11-19
AU2017238442A1 (en) 2018-10-11
GB201604806D0 (en) 2016-05-04
CA3018428C (en) 2024-03-19
EP4270007A2 (en) 2023-11-01
SG11201807991QA (en) 2018-10-30
EP3433616B1 (en) 2020-12-30
JP2019510974A (ja) 2019-04-18
CA3018428A1 (en) 2017-09-28
EP3839513A1 (en) 2021-06-23
EP3839513C0 (en) 2023-06-14
ES2951136T3 (es) 2023-10-18
JP6777757B2 (ja) 2020-10-28
MY187655A (en) 2021-10-07
CN109313192B (zh) 2022-07-26
ES2861440T5 (en) 2025-02-05
CN109313192A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
JP6263474B2 (ja) ヌクレオソームアダクト検出法
KR102246699B1 (ko) 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도
AU2022207641A1 (en) Method for the detection of lung cancer
US20160003848A1 (en) Method for predicting therapy efficacy using nucleosome structure biomarkers
TW201930881A (zh) 大腸直腸腺瘤之檢測及治療方法
TWI757285B (zh) 癌症偵測方法
HK40055426A (en) Use of dna-transcription factor complexes for cancer detection
HK40003771B (en) Use of nucleosome-transcription factor complexes for cancer detection
HK1249176B (en) Method for detecting nucleosome adducts

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250427

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250427

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250427